Literature DB >> 16917109

IL-20 and atherosclerosis: another brick in the wall.

Giuseppina Caligiuri, Srini V Kaveri, Antonino Nicoletti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917109     DOI: 10.1161/01.ATV.0000237564.81178.bb

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  4 in total

1.  Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss.

Authors:  Yu-Hsiang Hsu; Wei-Yu Chen; Chien-Hui Chan; Chih-Hsing Wu; Zih-Jie Sun; Ming-Shi Chang
Journal:  J Exp Med       Date:  2011-08-15       Impact factor: 14.307

2.  Interleukin-20 targets podocytes and is upregulated in experimental murine diabetic nephropathy.

Authors:  Yu-Hsiang Hsu; Hsing-Hui Li; Junne-Ming Sung; Wei-Yu Chen; Ya-Chin Hou; Yun-Han Weng; Wei-Ting Lai; Chih-Hsing Wu; Ming-Shi Chang
Journal:  Exp Mol Med       Date:  2017-03-31       Impact factor: 8.718

3.  Anti-IL-20 antibody improved motor function and reduced glial scar formation after traumatic spinal cord injury in rats.

Authors:  Jung-Shun Lee; Yu-Hsiang Hsu; Yi-Shu Chiu; I-Ming Jou; Ming-Shi Chang
Journal:  J Neuroinflammation       Date:  2020-05-14       Impact factor: 8.322

4.  Common Variants in IL-20 Gene are Associated with Subclinical Atherosclerosis, Cardiovascular Risk Factors and IL-20 Levels in the Cohort of the Genetics of Atherosclerotic Disease (GEA) Mexican Study.

Authors:  Javier Angeles-Martínez; Rosalinda Posadas-Sánchez; Eyerahi Bravo-Flores; María Del Carmen González-Salazar; Gilberto Vargas-Alarcón
Journal:  Biomolecules       Date:  2020-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.